News | Atrial Fibrillation | May 19, 2020

Heart Tissue Changes Can Predict Atrial Fibrillation Prior to Onset

PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling

PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell

May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the late-breaking PREDICT-AF trial showed first time there is extensive extracellular matrix (ECM) remodeling, which can be used as a new predictor for AF. The study was presented at the Heart Rhythm Society (HRS) 2020 Science virtual meeting.

The Tissue, Blood and Biomarkers to Predict Future Atrial Fibrillation (PREDICT-AF) study showed that extensive ECM remodeling, reaching beyond the deposition of collagens, takes place in the atria of patients long before they develop AF, said Joris R. de Groot, M.D., Ph.D., Amsterdam UMC, Amsterdam, Netherlands, who presented the results. He said the high accuracy of a gene panel to predict future AF may inspire further research to provide targets for diagnosis and primary prevention of AF.

The study included 150 patients (age 68±7 years, 87% men, 115 CABG, 11 valve surgery, 24 combined surgeries). Patients without a history of AF undergoing cardiothoracic surgery with a CHA2DS2-VASc score ≥2 were included and the left atrial appendage was excised (PREDICT-AF NCT03130985). Rhythm monitoring with multiple Holters was performed for 2 years. The primary endpoint was late-onset AF: any atrial tachyarrhythmia >30 sec, occurring >50 days after surgery. The expression of 25 genes related to structural or electrical remodeling was quantified with qPCR in all patients and associated with late-onset AF using Cox-regression analyses. Genes were selected based on a discovery phase (transcriptome sequencing of 22 atrial tissues). Gene panels were used to determine C-statistics.[1] 

Median follow-up was two years [1.5-2]. Post-operative AF occurred in 63 (42%) patients ≤50 days post-surgery and late-onset AF in 18 (12%). Gene expression of all 25 genes was similar in patients with and without post-operative AF <50 days. Patients with late-onset AF exhibited numerical down regulation of KCNJ2 and up regulation of SCN2B. There was a marked increased expression of extracellular matrix (ECM) genes encoding collagens and matricellular proteins that act as structural proteins and fibrogenic mediators. We found a strong correlation between ECM genes and the fibroblast activator Endothelin-1. 

The fraction of Vimentin positive cells (i.e. fibroblasts) was similar, suggesting fibroblast activation rather than proliferation. A gene panel including KCNJ2, COL8A2, and COL1A1 better discriminated late-onset AF (AUC=0.82) than a model with the most relevant clinical parameters (age≥75, LAVI and sex; AUC=0.69).

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

Reference:

1. PREventive Left Atrial appenDage Resection for the predICtion of fuTure Atrial Fibrillation: Design of the PREDICT AF Study. J Cardiovasc Med (Hagerstown). 2019 Nov;20(11):752-761. doi: 10.2459/JCM.0000000000000868.

 


Related Content

News | Atrial Fibrillation

November 30, 2023 — Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a ...

Home November 30, 2023
Home
News | Atrial Fibrillation

November 24, 2023 — During the American Heart Association Scientific Sessions 2023, held recently in Philadephia, PA ...

Home November 22, 2023
Home
News | Atrial Fibrillation

November 10, 2023 — Cardiologists, cardiothoracic surgeons and interventionalists from the Smidt Heart Institute at ...

Home November 10, 2023
Home
News | Atrial Fibrillation

November 6, 2023 — Atrial fibrillation (AF) diagnosis was associated with a 45% increased risk of mild cognitive ...

Home November 06, 2023
Home
News | Atrial Fibrillation

October 6, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home October 06, 2023
Home
News | Atrial Fibrillation

August 31, 2023 — Atrial fibrillation ablation is associated with lower rates of death, urgent heart transplantation or ...

Home August 31, 2023
Home
News | Atrial Fibrillation

August 24, 2023 — GE HealthCare announces the launch of CardioVisio for Atrial Fibrillation (AFib), a digital tool ...

Home August 24, 2023
Home
News | Atrial Fibrillation

August 23, 2023 — Atrial fibrillation, or AFib , is the most common heart rhythm problem, affecting millions of ...

Home August 23, 2023
Home
News | Atrial Fibrillation

July 21, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home July 21, 2023
Home
News | Atrial Fibrillation

July 7, 2023 — Atrial fibrillation (AFib) is the most common type of heart arrhythmia. This serious condition occurs ...

Home July 07, 2023
Home
Subscribe Now